Antiphospholipid and Antinuclear Antibodies in Children with Idiopathic Epilepsy: A 2-Year Prospective Study

다국어 초록 (Multilingual Abstract)

Background and Purpose The high prevalence of antiphospholipid antibodies (aPL) and antinuclear antibodies (ANA) in patients with epilepsy may be associated with either the disease itself or the antiepileptic treatment. The purpose of this prospective study was to determine the prevalence of aPL and ANA in children with idiopathic epilepsy before and during treatment with antiepileptic drugs.
Methods aPL, including both anticardiolipin and anti-β2-glycoprotein I antibodies, and ANA statuses were determined in 40 healthy children, 30 children treated with sodium valproate (VPA) monotherapy, and 20 children treated with carbamazepine (CBZ) monotherapy before and at 6, 12, and 24 months after treatment initiation.
Results Fifteen children (50%) in the VPA-treated group and 7 (35%) in the CBZ-treated group showed positivity for aPL before treatment initiation, compared with only 4 of the 40 controls. Nine children (30%) in the VPA-treated group and 4 (20%) in the CBZ-treated group showed positivity for ANA before treatment initiation, compared with only 2 of the 40 controls. The subgroup analysis found nonsignificant associations at the different time points regarding the positivity of all of the autoantibodies. Only patients treated with VPA had a significantly decreased risk of aPL positivity after 6 months of treatment.
Conclusions The increased prevalence of autoantibodies in children with idiopathic epilepsy is strongly associated with the disease itself.

참고문헌 (Reference)

1 Liimatainen S, "The high prevalence of antiphospholipid antibodies in refractory focal epilepsy is related to recurrent seizures" 16 : 134-141, 2009

2 Arnson Y, "The antiphospholipid syndrome as a neurological disease" 40 : 97-108, 2010

3 Constantin T, "Prevalence of antiphospholipid and antinuclear antibodies in children with epilepsy" 15 : CR164-CR169, 2009

4 Cimaz R, "Prevalence of anti-cardiolipin, anti-β2 glycoprotein I, and anti-prothrombin antibodies in young patients with epilepsy" 43 : 52-59, 2002

5 Verrot D, "Prevalence and signification of antinuclear and anticardiolipin antibodies in patients with epilepsy" 103 : 33-37, 1997

6 Angelini L, "Partial seizures associated with antiphospholipid antibodies in childhood" 29 : 249-253, 1998

7 Agmon-Levin N, "International recommendations for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies" 73 : 17-23, 2014

8 Eriksson K, "High prevalence of antiphospholipid antibodies in children with epilepsy : a controlled study of 50 cases" 46 : 129-137, 2001

9 Julian T, "Gluten sensitivity and epilepsy : a systematic review" 266 : 1557-1565, 2019

10 Specchio N, "Epileptic encephalopathy in children possibly related to immune-mediated pathogenesis" 32 : 51-56, 2010

11 Dlott JS, "Drug-induced lupus anticoagulants and antiphospholipid antibodies" 14 : 71-78, 2012

12 Rumsey DG, "Diagnosis and treatment of antiphospholipid syndrome in childhood : a review" 67 : 34-40, 2017

13 Graf J, "Central nervous system manifestations of antiphospholipid syndrome" 43 : 547-560, 2017

14 Brey RL, "Antiphospholipid antibodies and the brain : a consensus report" 20 : 153-157, 2011

15 Peltola JT, "Antiphospholipid and antinuclear antibodies in patients with epilepsy or new-onset seizure disorders" 109 : 712-717, 2000